New paper: "...CCR5 and CXCR4 Antagonists in Carci
Post# of 155540
(Total Views: 891)
Posted On: 01/01/2023 11:42:53 PM
New paper: "...CCR5 and CXCR4 Antagonists in Carcinomas"
A couple of highlights (culled from different sections of the paper):
Moreover, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in colorectal cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma, including clinical trials. These results reveal new alternatives to this therapy for human carcinomas.
The HIV-associated chemokine receptor (CCR5 and CXCR4) antagonists have critical roles in inhibiting cell migration, invasion, and metastasis and can modulate the tumoral immune response through Treg regulation.
For more, load link below and click on "Read full-text":
https://www.researchgate.net/publication/3666...Carcinomas
Also worth noting (from a different article linked below):
"Oncology Market Size to Hit US $581.25 Billion by 2030"
"Based on the indication, the breast cancer is estimated to be the most opportunistic segment during the forecast period. This is mainly due to the alarming rise in the breast cancer cases across the globe."
https://www.globenewswire.com/en/news-release...-2030.html
Some details on Leronlimab's possible role in all of the above:
https://www.cytodyn.com/pipeline/oncology
A couple of highlights (culled from different sections of the paper):
Moreover, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in colorectal cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma, including clinical trials. These results reveal new alternatives to this therapy for human carcinomas.
The HIV-associated chemokine receptor (CCR5 and CXCR4) antagonists have critical roles in inhibiting cell migration, invasion, and metastasis and can modulate the tumoral immune response through Treg regulation.
For more, load link below and click on "Read full-text":
https://www.researchgate.net/publication/3666...Carcinomas
Also worth noting (from a different article linked below):
"Oncology Market Size to Hit US $581.25 Billion by 2030"
"Based on the indication, the breast cancer is estimated to be the most opportunistic segment during the forecast period. This is mainly due to the alarming rise in the breast cancer cases across the globe."
https://www.globenewswire.com/en/news-release...-2030.html
Some details on Leronlimab's possible role in all of the above:
https://www.cytodyn.com/pipeline/oncology
(12)
(0)